Christobel Selecky Sells $871K of ImmunityBio Inc (IBRX) — SEC Form 4, Jul 01, 2026
Open-Market Net Sale · SEC Form 4
−$871,216
10b5-1 Plan
Equity Position
95.7K sh
95,722 → 95,722
Filing Lag
1 business day
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Christobel Selecky CIK 0001849739 |
Director
|
Christobel Selecky at ImmunityBio Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$2,997,932
More from this insider at ImmunityBio Inc
| 2026-07-07 | Sell | -$1,439,066 | View |
| 2026-06-11 | Award | — | View |
| 2026-02-25 | Sell | -$250,000 | View |
| 2026-01-22 | Sell | -$437,650 | View |
| 2025-06-20 | Award | — | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-06-29 | M - Exercise 10b5-1 | 32,173 A | $2.98 | +$95,876 | 32,173 | Direct |
| Common Stock | 2026-06-29 | M - Exercise 10b5-1 | 33,549 A | $2.99 | +$100,312 | 65,722 | Direct |
| Common Stock | 2026-06-29 | M - Exercise 10b5-1 | 30,000 A | $2.84 | +$85,200 | 95,722 | Direct |
| Common StockF1F2 | 2026-06-29 | S - Sale 10b5-1 | 95,722 D | $9.01 | -$862,216 | 0 | Direct |
| Common Stock | 2026-06-30 | M - Exercise 10b5-1 | 700 A | $2.98 | +$2,086 | 700 | Direct |
| Common StockF1 | 2026-06-30 | S - Sale 10b5-1 | 1,000 D | $9.00 | -$9,000 | 0 | Direct |
| Common Stock | 2026-06-30 | M - Exercise 10b5-1 | 300 A | $2.99 | +$897 | 1,000 | Direct |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | $2.98 | 2026-06-29 | M - Exercise 10b5-1 | 32,173 D | $0.00 | 2032-06-14 | 32,173 Common Stock | Direct |
| Stock Option (right to buy) | $2.99 | 2026-06-29 | M - Exercise 10b5-1 | 33,549 D | $0.00 | 2033-06-13 | 33,549 Common Stock | Direct |
| Stock Option (right to buy) | $2.84 | 2026-06-29 | M - Exercise 10b5-1 | 30,000 D | $0.00 | 2035-06-18 | 30,000 Common Stock | Direct |
| Stock Option (right to buy) | $2.98 | 2026-06-30 | M - Exercise 10b5-1 | 700 D | $0.00 | 2032-06-14 | 700 Common Stock | Direct |
| Stock Option (right to buy) | $2.99 | 2026-06-30 | M - Exercise 10b5-1 | 300 D | $0.00 | 2033-06-13 | 300 Common Stock | Direct |
Footnotes (2)
- F1
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026. Show more
- F2
- Represents the weighted average share price of an aggregate total of 95,722 shares sold in the price range of $9.00 to $9.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Show more
Related filings at ImmunityBio Inc
Institutional Holders
13F holders · Jun 30, 2026
404
institutional managers reporting a position
Largest by reported value
- Black Rock, Inc. $298M
- State Street Corporation $187M
- Vanguard Portfolio Management Llc $156M
5%+ Holders · 13D/G
1 filer
-
Cambridge Equities, LP 64.8%
Other insiders at ImmunityBio Inc
-
Barry J. Simon -$269K
-
Cheryl Cohen -$851K
-
Cheryl Cohen -$1.25M
-
Barry J. Simon -$197K
GET /v1/forms/4/0001849739-26-000011
API docs
View Original SEC Filing